Meyka Pro banner
Merck & Co., Inc.

Stay Updated with the Latest Merck & Co., Inc. MRK News in Real Time

Find MRK news now at Meyka AI. Stay informed with the latest Merck & Co., Inc. stocks updates, including price news, market analysis, and expert insights.

MRKNYSE
HealthcareDrug Manufacturers - General
$152.55
$3.56(2.39%)
U.S. Market opens in 63h 30m
Block Ordered to Pay $120M CFPB Restitution for Cash App Fraud Failures
📅 in about 4 hours

Block Ordered to Pay $120M CFPB Restitution for Cash App Fraud Failures

Block must pay $45M to states and $75M-$120M to Cash App users via CFPB restitution for fraud failures, account security gaps, and inadequate customer support.

Read more 12
Bitcoin Price Today: BTC Soars 8% to $74,982 as Crypto Rally Explodes; Ethereum, XRP Surge
📅 9 hours ago

Bitcoin Price Today: BTC Soars 8% to $74,982 as Crypto Rally Explodes; Ethereum, XRP Surge

Bitcoin surged 8% to $74,982 on Friday, August 21, 2026, extending a powerful weekly rally. The cryptocurrency has now climbed nearly 20% since Monday, fueled by a surprise US Treasury policy shift. Ethereum jumped toward $2,300, gaining roughly 18% in 24 hours, while XRP surged past $1.25.  Total crypto market capitalization reached $2.56 trillion, up…

Read more 12
Tech Stocks to Watch: Alphabet Lifts 2026 Capex Forecast to $195B-205B
📅 11 hours ago

Tech Stocks to Watch: Alphabet Lifts 2026 Capex Forecast to $195B-205B

Alphabet is spending more to keep up with demand for artificial intelligence. On July 22, 2026, the Google parent raised its 2026 capital expenditure forecast to $195 billion-$205 billion, up from $180 billion-$190 billion. The increase comes as Google Cloud revenue jumped 82% to $24.8 billion in the second quarter. As AI demand drives higher…

Read more 12
Moderna Tumbles 23.5% After 177% Surge on Cancer Vaccine Win, August 21
📅 18 hours ago

Moderna Tumbles 23.5% After 177% Surge on Cancer Vaccine Win, August 21

Moderna stock fell 23.5% to $133.32 on August 21 after surging 177% the prior day on its cancer vaccine breakthrough with Merck. RSI hit record 92.21, signaling extreme overbought conditions.

Read more 12
Moderna Soars 122% on Melanoma Vaccine Breakthrough, August 21
📅 1 day ago

Moderna Soars 122% on Melanoma Vaccine Breakthrough, August 21

Moderna stock jumps 122% after announcing its personalized mRNA melanoma vaccine met Phase 3 trial goals. The vaccine reduced cancer recurrence and spread when combined with Merck’s Keytruda.

Read more 12
Moderna Soars 177% on Melanoma Vaccine Win; Merck Gains 12% on August 20
📅 1 day ago

Moderna Soars 177% on Melanoma Vaccine Win; Merck Gains 12% on August 20

Moderna jumps 177% and Merck rises 12% after their mRNA cancer vaccine meets Phase 3 endpoints for melanoma. The combo reduced cancer recurrence and spread in over 1,100 patients.

Read more 12
Crypto Prices Today: Bitcoin Hits $69,551, Ethereum Gains 17.74% as Hyperliquid Surges 20.97%
📅 1 day ago

Crypto Prices Today: Bitcoin Hits $69,551, Ethereum Gains 17.74% as Hyperliquid Surges 20.97%

Crypto prices surged sharply on Thursday, August 20, 2026, breaking weeks of sideways trading. Bitcoin jumped to $69,551, gaining roughly 8% in 24 hours. Ethereum climbed 17.74% to reclaim the $2,000 level, while Hyperliquid’s HYPE token surged 20.97%. The rally followed a surprise US Treasury announcement to double its long-dated bond buyback operations.  Total crypto…

Read more 12
NVDA Stock, AMD Stock, Micron and Broadcom Gain as AI Spending Estimates Rise
📅 1 day ago

NVDA Stock, AMD Stock, Micron and Broadcom Gain as AI Spending Estimates Rise

AI spending estimates are rising again, giving semiconductor stocks a fresh boost. On August 7, 2026, Goldman Sachs estimated global AI investment could reach about $1 trillion this year, above widely cited hyperscaler spending forecasts. That outlook is supporting demand for AI chips, memory and networking hardware. As a result, NVDA stock, AMD stock, Micron…

Read more 12
Moderna Soars 177% After Melanoma Vaccine Clears Phase 3 Trial on August 20
📅 1 day ago

Moderna Soars 177% After Melanoma Vaccine Clears Phase 3 Trial on August 20

Moderna stock jumped 177% after its melanoma vaccine met Phase 3 trial endpoints. The personalized mRNA therapy showed significant improvements over standard treatment in over 1,100 patients.

Read more 12

MRK News FAQ